Sertoli-Leydig Cell Tumour in a Patient with Ambiguous Genitalia and Congenital Adrenal Hyperplasia
Article Sidebar
Main Article Content
Abstract
Background: Hyperandrogenism, characterized by elevated levels of male hormones such as testosterone, presents various clinical manifestations including secondary amenorrhea, hirsutism, and clitoromegaly. While often associated with polycystic ovarian syndrome, other differentials such as Sertoli-Leydig cell tumors and Congenital Adrenal Hyperplasia (CAH) are critical to consider. These conditions can manifest at different life stages and are seldom seen together.
Objective: This case study aims to explore the rare co-presentation of CAH and a Sertoli-Leydig cell tumor in a patient presenting with secondary amenorrhea and ambiguous genitalia, and to discuss the diagnostic challenges and management strategies involved.
Methods: A 16-year-old female presented with irregular menstrual cycles and secondary amenorrhea, alongside symptoms of hyperandrogenism such as voice deepening and hirsutism. Diagnostic procedures included physical examinations, ultrasound imaging, and hormone level assessments. A detailed ultrasound revealed a large right-sided ovarian mass, and biopsies confirmed a Sertoli-Leydig cell tumor. Surgical intervention involved the excision of the mass, with subsequent histopathological examination. The patient underwent three cycles of chemotherapy and was scheduled for reconstructive surgery.
Results: Ultrasound dimensions of the ovarian mass were 7.2 x 13.4 x 16 cm, with the post-surgical tumor measuring 18 x 17 cm. Laboratory findings included testosterone levels above 200 ng/ml, and elevated alpha-fetoprotein levels. The histopathological report confirmed a poorly differentiated Sertoli-Leydig cell tumor (FIGO stage 1a). Post-treatment follow-up showed a marked reduction in androgen levels and stabilization of the patient's menstrual cycle.
Conclusion: The coexistence of CAH and a Sertoli-Leydig cell tumor presents unique diagnostic and therapeutic challenges. This case emphasizes the importance of a thorough evaluation and a multidisciplinary approach in the management of complex hyperandrogenic states to achieve optimal clinical outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Stefanaki K, Ilias I, Paschou SA, Karagiannakis DS. Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS?. Hormones. 2023 Dec;22(4):715-24.
Sharma A, Welt CK. Practical Approach to Hyperandrogenism in Women. Med Clin North Am. 2021 Nov;105(6):1099-1116. doi: 10.1016/j.mcna.2021.06.008. Epub 2021 Sep 8. PMID: 34688417; PMCID: PMC8548673.
Chen M, Zhou W, Zhang Z, Zou Y, Li C. An Ovarian Leydig Cell Tumor of Ultrasound Negative in a Postmenopausal Woman with Hirsutism and Hyperandrogenism: A Case Report. Medicine (Baltimore). 2018 Mar;97(10):e0093. doi: 10.1097/MD.0000000000010093. PMID: 29517680; PMCID: PMC5882447.
Faria AM, Perez RV, Marcondes JA, Freire DS, Blasbalg R, Soares J Jr, Simões K, Hayashida SA, Pereira MA. A Premenopausal Woman with Virilization Secondary to an Ovarian Leydig Cell Tumor. Nat Rev Endocrinol. 2011 Apr;7(4):240-5. doi: 10.1038/nrendo.2011.15. Epub 2011 Feb 15. PMID: 21321567.
Guo Z, Jin F, Chen S, Hu P, Hao Y, Yu Q. Correlation between biochemical and clinical hyperandrogenism parameter in polycystic ovary syndrome in relation to age. BMC Endocrine Disorders. 2023 Apr 23;23(1):89.
Kozan P, Chalasani S, Handelsman DJ, Pike AH, Crawford BA. A Leydig Cell Tumor of the Ovary Resulting in Extreme Hyperandrogenism, Erythrocytosis, and Recurrent Pulmonary Embolism. J Clin Endocrinol Metab. 2014 Jan;99(1):12-17. doi: 10.1210/jc.2013-3108.
Horta M, Cunha TM. Sex Cord-Stromal Tumors of the Ovary: A Comprehensive Review and Update for Radiologists. Diagn Interv Radiol. 2015;21:277–86. doi: 10.5152/dir.2015.34414.
Brandone N, Borrione C, Rome A, de Paula AM. Ovarian Sertoli-Leydig Tumor: A Tricky Tumor. Ann Pathol. 2018;38:131–136.
Prunty FT. Hirsutism: Virilism and Apparent Virilism and Their Gonadal Relationship. II. J Endocrinol. 1967;38:203–227.
Meldrum DR, Abraham GE. Peripheral and Ovarian Venous Concentrations of Various Steroid Hormones in Virilizing Ovarian Tumors. Obstet Gynecol. 1979;53:36–43.
Wilkinson N, Osborn S, Youngh RH. Sex Cord-Stromal Tumors of the Ovary: A Review Highlighting Recent Advances. Diagn Histopathol. 2008;14:388–400.
Pietro L, Carlo S, Lorena C, et al. Sertoli-Leydig Cell Tumors: Current Status of Surgical Management: Literature Review and Proposal of Treatment. Gynecol Endocrinol. 2013;29(5):412–417.
Yadav V, Sharma Y. Hyperandrogenism. Indian Journal of Pediatrics. 2023 Oct;90(10):1018-24.
Chen FY, Sheu BC, Lin MC, Chow SN, Lin HH. Sertoli-Leydig Cell Tumor of the Ovary. J Formos Med Assoc. 2004;103:388–391.
Sachdeva P, Arora R, Dubey C, Sukhija A, Daga M, Sing DK. Sertoli-Leydig Cell Tumor: A Rare Ovarian Neoplasm. Case Report and Review of Literature. Gynaecol Endocrinol. 2008;24:230–234.
Hirschberg AL. Approach to investigation of hyperandrogenism in a postmenopausal woman. The Journal of Clinical Endocrinology & Metabolism. 2023 May 1;108(5):1243-53.
Kamata Y, Hayashi A, Ogawa A, et al. A Woman with Salt-Wasting Congenital Adrenal Hyperplasia Presenting with a Mucinous Ovarian Cystadenoma During Pregnancy. Intern Med. 2011;50:1981–5. doi: 10.2169/internalmedicine.50.5401.
Fontes AF, Reis FM, Candido AL, Gomes KB, Tosatti JA. Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized clinical trials. European Journal of Clinical Pharmacology. 2023 Apr;79(4):445-60.
Xiang Y, Wang H, Ding H, Xu T, Liu X, Huang Z, Wu H, Ge H. Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia. International Immunopharmacology. 2023 Dec 1;125:111141.
Al-Ahmadie HA, Stanek J, Liu J, et al. Ovarian 'Tumor' of the Adrenogenital Syndrome: The First Reported Case. Am J Surg Pathol. 2001 Nov;25(11):1443–50. doi: 10.1097/00000478-200111000-00015.